Newsletter

Newsletter November 2019

Read in web browser CEO comments As the days get shorter and the darkness falls earlier and earlier for each day, I am very happy about the many good news that has come to characterize Cyxone lately, which is also reflected in this newsletter. Most central is among other things the successful TO3 that expired […]

Read More

Newsletter September 2019

Read in web browser CEO comments During the recent months, we have been able to communicate milestones that we, together with our collaboration partners, have worked hard to fulfill. Both T20K and Rabeximod have during summer taken strong steps forward in their respective development plans in accordance with objectives set during our preparatory work in […]

Read More

Newsletter June 2019

Read in web browser CEO comments At last, it has finally become time to resume communication with your shareholders via newsletters. Cyxone has kept a low profile while we prepared for our clinical studies and now, when we have reached clinical development with both of our candidates, we can finally start sharing more about what […]

Read More

Newsletter July 2018

There are many who show great interest for Cyxone and our drug candidates. We are pleased about the discussions happening around the effects of T20K and Rabeximod and what it can lead to in the future. Since there seems to be a lot that should be commented and explained, we would like to provide both […]

Read More

Newsletter April 2018

We are right in the middle of an exciting period for Cyxone with a lot of moving pieces and I get a lot of questions from shareholders that I would like to answer, but I am not always able to for different reasons. Our biggest focus in the recent months has been to finalize the […]

Read More